Increasing concentrations of intravitreal therapies for neovascular age-related macular degeneration

Age-related macular degeneration (AMD), a leading cause of blindness, is projected to affect 288 million people globally in 2040 from an estimate of 196 million in 2020.1 The vision-threatening late forms of the disease include neovascular AMD (nAMD) and geographical atrophy. In 2006, the US Food and Drug Administration (FDA) approved intravitreal injections of anti-vascular endothelial growth factor inhibiting drugs for the treatment of nAMD.2,3 These new treatment strategies of intraocular injections resulted in unprecedented visual acuity gains in eyes that, in the past, have experienced relentless vision loss despite therapies such as laser and photodynamic therapy.